Britain is losing its chance to become a life sciences superpower

We had a glimpse of the future with the announcement that the government is partnering with BioNTech to trial innovative cancer vaccines in the UK. These mRNA vaccines, tailored to each tumour’s genetic code, are designed to harness patients’ immune systems. This is a potentially game-changing approach, which promises to protect patients against cancer in the same way as mRNA vaccines protect against severe Covid-19. This may also lower care costs since tumour sequencing and vaccination should be far cheaper than existing immunotherapy treatments.

Veja mais